Provided is a method of treating a distal tumor in an individual by administering a chimeric poliovirus to a first tumor in an effective amount to induce an antitumor immune response effective to treat a distal tumor.

Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.

Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided.

Recombinant oncolytic viruses for expression of sialidase and their use in the treatment of cancer, particularly solid tumors, are described.

Recombinant oncolytic viruses for expression of sialidase and their use in the treatment of cancer, particularly solid tumors, are described.

Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.

Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.